全球陣發性睡眠性血紅蛋白尿藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

全球陣發性睡眠性血紅蛋白尿藥物市場需求預計將從 2022 年的 57.1 億美元增至 2030 年的近 147.4 億美元，2023-2030 年研究期間CAGR為 12.6%。

陣發性睡眠性血紅蛋白尿 (PNH) 藥物是專門用於治療和控制陣發性夜間血紅蛋白尿（一種罕見且可能危及生命的血液疾病）的藥物。其特徵是紅血球異常分解，導致尿液中出現血紅素、血栓，並增加貧血、疲勞和器官損傷等併發症的風險。

市場動態

PNH 的罕見性及其被歸類為罕見疾病導致醫療需求未被滿足，從而鼓勵了該領域的研究和開發。生物製藥的進步，特別是像依庫珠單抗 (Soliris) 這樣的單株抗體，改變了 PNH 的治療。由於 PNH 藥物的罕見性，其被指定為孤兒藥，這為製藥公司提供了誘因。意識和診斷能力的提高導致更多的 PNH 診斷，從而增加了對有效藥物的需求。全球人口老化，PNH 在成年人中更為普遍，進一步放大了市場潛力。策略合作和夥伴關係加速了藥物開發，而醫療保健基礎設施和報銷政策則影響患者的取得。正在進行的臨床試驗和研究計劃透過探索新的治療選擇來促進市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球陣發性睡眠性血紅素尿症藥物市場的各個細分市場進行了包容性評估。陣發性睡眠性血紅蛋白尿藥物產業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的陣發性睡眠性血紅蛋白尿藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。陣發性睡眠性血紅素尿症藥物市場的主要參與者包括Alexion Pharmaceuticals、Takeda Pharmaceutical Company Limited (Shire Plc)、Akari Therapeutics、Apellis Pharmaceuticals、Ra Pharmaceuticals、Achillion Pharmaceuticals、Amgen Inc.、Regeneron Pharmaceuticals, Inc.、Fceuticals, Inc.、Fceutical . Hoffmann-La羅氏公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法論
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：陣發性睡眠性血紅素尿藥 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 按處理方式進行的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球陣發性睡眠性血紅素尿藥市場分析：依治療分類

• 按治療概述
• 歷史和預測數據
• 按治療分析
• 藥物
• 幹細胞移植
• 輸血

第 6 章：全球陣發性夜間血紅蛋白尿藥物市場分析：按地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區國家/地區銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 7 章：陣發性睡眠性血紅素尿藥公司的競爭格局

• 陣發性睡眠性血紅素尿藥市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 8 章：公司簡介

• 公司股份分析
• 市場集中度
• Alexion Pharmaceuticals
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Takeda Pharmaceutical Company Limited (Shire Plc)
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Akari Therapeutics
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Apellis Pharmaceuticals
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Ra Pharmaceuticals
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Achillion Pharmaceuticals
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Amgen Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Regeneron Pharmaceuticals Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• F. Hoffmann-La Roche AG.
• 公司簡介
• 公司收入
• 產品
• 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

The global demand for Paroxysmal Nocturnal Hemoglobinuria Drug Market is presumed to reach the market size of nearly USD 14.74 BN by 2030 from USD 5.71 BN in 2022 with a CAGR of 12.6% under the study period 2023 - 2030.

Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs are medications designed to treat and manage Paroxysmal Nocturnal Hemoglobinuria, a rare and potentially life-threatening blood disorder. It is characterized by the abnormal breakdown of red blood cells, leading to hemoglobin in the urine, blood clots, and an increased risk of complications such as anemia, fatigue, and organ damage.

MARKET DYNAMICS

The rarity of PNH and its classification as a rare disease contribute to an unmet medical need, encouraging research and development in the field. Advances in biopharmaceuticals, particularly monoclonal antibodies like eculizumab (Soliris), have transformed PNH treatment. Orphan drug designation for PNH drugs, driven by the condition's rarity, provides incentives for pharmaceutical companies. Increased awareness and diagnostic capabilities lead to more PNH diagnoses, boosting the demand for effective drugs. The global aging population, with PNH more prevalent in adults, further amplifies market potential. Strategic collaborations and partnerships accelerate drug development, while healthcare infrastructure and reimbursement policies influence patient access. Ongoing clinical trials and research initiatives contribute to market growth by exploring new therapeutic options.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of paroxysmal nocturnal hemoglobinuria drug. The growth and trends of paroxysmal nocturnal hemoglobinuria drug industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the paroxysmal nocturnal hemoglobinuria drug market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

• Medication
• Stem Cell Transplant
• Blood Transfusion

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Paroxysmal Nocturnal Hemoglobinuria Drug market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Paroxysmal Nocturnal Hemoglobinuria Drug market include Alexion Pharmaceuticals, Takeda Pharmaceutical Company Limited (Shire Plc), Akari Therapeutics, Apellis Pharmaceuticals, Ra Pharmaceuticals, Achillion Pharmaceuticals, Amgen Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Treatment
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET ANALYSIS BY TREATMENT

• 5.1 Overview by Treatment
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Treatment
• 5.4 Medication Historic and Forecast Sales by Regions
• 5.5 Stem Cell Transplant Historic and Forecast Sales by Regions
• 5.6 Blood Transfusion Historic and Forecast Sales by Regions

6 . GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET ANALYSIS BY GEOGRAPHY

• 6.1. Regional Outlook
• 6.2. Introduction
• 6.3. North America Sales Analysis
  • 6.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.3.2. North America By Segment Sales Analysis
  • 6.3.3. North America By Country Sales Analysis
  • 6.3.4. United State Sales Analysis
  • 6.3.5. Canada Sales Analysis
  • 6.3.6. Mexico Sales Analysis
• 6.4. Europe Sales Analysis
  • 6.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.4.2. Europe by Segment Sales Analysis
  • 6.4.3. Europe by Country Sales Analysis
  • 6.4.4. United Kingdom Sales Analysis
  • 6.4.5. France Sales Analysis
  • 6.4.6. Germany Sales Analysis
  • 6.4.7. Italy Sales Analysis
  • 6.4.8. Russia Sales Analysis
  • 6.4.9. Rest Of Europe Sales Analysis
• 6.5. Asia Pacific Sales Analysis
  • 6.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.5.2. Asia Pacific by Segment Sales Analysis
  • 6.5.3. Asia Pacific by Country Sales Analysis
  • 6.5.4. China Sales Analysis
  • 6.5.5. India Sales Analysis
  • 6.5.6. Japan Sales Analysis
  • 6.5.7. South Korea Sales Analysis
  • 6.5.8. Australia Sales Analysis
  • 6.5.9. South East Asia Sales Analysis
  • 6.5.10. Rest Of Asia Pacific Sales Analysis
• 6.6. Latin America Sales Analysis
  • 6.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.6.2. Latin America by Segment Sales Analysis
  • 6.6.3. Latin America by Country Sales Analysis
  • 6.6.4. Brazil Sales Analysis
  • 6.6.5. Argentina Sales Analysis
  • 6.6.6. Peru Sales Analysis
  • 6.6.7. Chile Sales Analysis
  • 6.6.8. Rest of Latin America Sales Analysis
• 6.7. Middle East & Africa Sales Analysis
  • 6.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.7.2. Middle East & Africa by Segment Sales Analysis
  • 6.7.3. Middle East & Africa by Country Sales Analysis
  • 6.7.4. Saudi Arabia Sales Analysis
  • 6.7.5. UAE Sales Analysis
  • 6.7.6. Israel Sales Analysis
  • 6.7.7. South Africa Sales Analysis
  • 6.7.8. Rest Of Middle East And Africa Sales Analysis

7 . COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG COMPANIES

• 7.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Competition
• 7.2. Partnership/Collaboration/Agreement
• 7.3. Merger And Acquisitions
• 7.4. New Product Launch
• 7.5. Other Developments

8 . COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG INDUSTRY

• 8.1. Company Share Analysis
• 8.2. Market Concentration Rate
• 8.3. Alexion Pharmaceuticals
  • 8.3.1. Company Overview
  • 8.3.2. Company Revenue
  • 8.3.3. Products
  • 8.3.4. Recent Developments
• 8.4. Takeda Pharmaceutical Company Limited (Shire Plc)
  • 8.4.1. Company Overview
  • 8.4.2. Company Revenue
  • 8.4.3. Products
  • 8.4.4. Recent Developments
• 8.5. Akari Therapeutics
  • 8.5.1. Company Overview
  • 8.5.2. Company Revenue
  • 8.5.3. Products
  • 8.5.4. Recent Developments
• 8.6. Apellis Pharmaceuticals
  • 8.6.1. Company Overview
  • 8.6.2. Company Revenue
  • 8.6.3. Products
  • 8.6.4. Recent Developments
• 8.7. Ra Pharmaceuticals
  • 8.7.1. Company Overview
  • 8.7.2. Company Revenue
  • 8.7.3. Products
  • 8.7.4. Recent Developments
• 8.8. Achillion Pharmaceuticals
  • 8.8.1. Company Overview
  • 8.8.2. Company Revenue
  • 8.8.3. Products
  • 8.8.4. Recent Developments
• 8.9. Amgen Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Revenue
  • 8.9.3. Products
  • 8.9.4. Recent Developments
• 8.10. Regeneron Pharmaceuticals Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Revenue
  • 8.10.3. Products
  • 8.10.4. Recent Developments
• 8.11. F. Hoffmann-La Roche AG.
  • 8.11.1. Company Overview
  • 8.11.2. Company Revenue
  • 8.11.3. Products
  • 8.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Treatment (USD MN)
• Medication Market Sales by Geography (USD MN)
• Stem Cell Transplant Market Sales by Geography (USD MN)
• Blood Transfusion Market Sales by Geography (USD MN)
• Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Paroxysmal Nocturnal Hemoglobinuria Drug Report
• Market Research Process
• Market Research Methodology
• Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Treatment
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis By Treatment (USD MN)
• Medication Market Sales by Geography (USD MN)
• Stem Cell Transplant Market Sales by Geography (USD MN)
• Blood Transfusion Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.